SUZHOU, China, July 15, 2025 /PRNewswire/ — Divamics, a trailblazer in AI-driven drug discovery, has underscored its pivotal role in advancing metabolic disease therapeutics through its state-of-the-art AI and molecular dynamics (MD) platform. This cutting-edge technology recently facilitated the successful design of BGeneral Motors1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as reported in the July 2025 issue of the Journal of Medicinal Chemistry. This achievement exemplifies Divamics’ consistent ability to empower its partners in expediting their drug discovery pipelines.
AI-Powered Efficiency & Precision in Collaborative Drug Discovery
Divamics’ platform was instrumental in optimizing peptide interactions to achieve superior receptor binding for BGeneral Motors1812. Preclinical studies revealed that BGeneral Motors1812 demonstrated enhanced in vitro potency, showing a 50% increase in effect. It also exhibited improved in vivo efficacy, including significant weight loss and an enhanced metabolic profile.
Mechanistic Breakthroughs Enabled by Divamics’ AI and Molecular Dynamics
The platform provides an in-depth, mechanistic understanding of drug-receptor interactions at the atomic level. For instance, the mutation of Ile(Me)24 to Gly(Me)24 resulted in improved anti-aggregation properties. Further AI-guided MD simulations unveiled how hydrophobic residues form a crucial hydrophobic cage with the receptor, stabilizing the molecule. Strategic alpha-carbon methylation of these residues, precisely guided by Divamics’ AI, ultimately led to the development of BGeneral Motors1812. This showcases the platform’s ability to identify and validate subtle yet critical structural enhancements that drive therapeutic efficacy in collaborative projects.
Validated Track Record in Empowering Drug Discovery
With its crucial contributions to two successful candidates—BGeneral Motors1812 and BGeneral Motors0504 (in Phase III clinical trials since 2024)—Divamics’ AI and molecular dynamics technology has demonstrated its deep expertise in advancing metabolic disease therapeutics. The repeated success in these collaborative projects highlights the platform’s potential to revolutionize drug discovery, enabling partners to deliver high-quality leads with unprecedented efficiency.
“Our collaboration with partners like Brightgene, which led to the publication of BGeneral Motors1812 in the Journal of Medicinal Chemistry and the advancement of BGeneral Motors0504 into Phase III, establishes Divamics’ AI and MD platform as a powerful engine for drug discovery in metabolic disease,” said Dr. John Zheng, CEO of Divamics. “The consistent success our technology brings to these collaborative efforts is not just accelerating the pace of discovery; it’s redefining how our partners can approach previously ‘undruggable’ targets and bring high-potential therapeutic leads to the clinic.”
Divamics remains committed to providing its cutting-edge AI and MD capabilities to advance the global drug development landscape.
https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01120.
Most Commented